FR - Merckle GmbH e.a. v. Sanofi Aventis

Paris Court of First Instance, 6 April 2012, Merckle GmbH, Ratiopharm GmbH and Teva Santé S.A.S.  vs. Sanofi Aventis (docket number 09/14154), with thanks to Barbara Bertholet and Jean-Baptiste Chanial (ADAMAS) for providing the case and head note

This decision relates to an action for a declaration of non-infringement initiated by Merckle GmbH, Ratiopharm GmbH and Labotaroire Ratiopharm (now Teva Santé S.A.S.) against EP 0 881 901 owned by Sanofi Aventis.

The subject-matter of EP 0 881 901 is a pharmaceutical composition containing a combination of active ingredients, wherein the active ingredients are clopidogrel and aspirin, notably used for the treatment of illness caused by platelet aggregation. Clopidogrel besylate and aspirin (INN acetylsalicylic acid) both belong to the public domain.